Levi & Korsinsky Addresses Class Action Lawsuit for MoonLake Immunotherapeutics
Levi & Korsinsky, a distinguished law firm, has notified investors of MoonLake Immunotherapeutics about a significant class action lawsuit. Investors holding shares in MoonLake Immunotherapeutics (NASDAQ: MLTX) are urged to take notice and potentially participate in this legal proceeding.
Understanding the Class Action Lawsuit
This lawsuit is designed to help those who may have experienced financial setbacks due to alleged securities fraud. The claims are specifically related to events that transpired between March 10, 2024, and September 29, 2025. If you invested in MoonLake during this period, you may be eligible to join the action.
Who is Affected?
The core objective of the lawsuit is to recover losses sustained by investors who were adversely impacted by the reported fraud. The firm seeks to class different investors under a unified group to streamline the legal process and improve the efficacy of the claims.
Allegations Against MoonLake Immunotherapeutics
Key allegations in the complaint suggest that the defendants made numerous false statements and omitted critical information that would have influenced investor decisions. These allegations include the nature of the company's drug candidate, SLK, purportedly being more effective than established treatments like BIMZELX, despite claims of shared molecular targets, leading to misleading public perception.
Next Steps for Investors
If you believe you have suffered losses related to your investment in MoonLake, it is crucial to act promptly. The deadline to request to be appointed lead plaintiff in this lawsuit is fast approaching. Although serving as a lead plaintiff may give you a more influential role in the proceedings, you are still entitled to any potential recovery even if you do not assume this role.
Zero Financial Risk for Class Members
One of the appealing aspects of class action lawsuits, particularly in this case, is that eligible class members typically do not incur any legal costs. In fact, participation in the lawsuit can lead to financial compensation without upfront payments or obligations. This underscores the importance of advocating for your rights without risking your resources.
Why Choose Levi & Korsinsky?
The longstanding track record of Levi & Korsinsky speaks for itself. With two decades of experience, the firm has successfully represented many investors, achieving settlements that total hundreds of millions of dollars. Their expertise lies in complex securities litigation, making them well-equipped to handle cases like the one involving MoonLake.
Contact Information for Further Inquiries
If you have any questions or wish to discuss your eligibility, you can reach out to Joseph E. Levi, Esq. He is available via email at jlevi@levikorsinsky.com or by phone at (212) 363-7500. The firm is based at 33 Whitehall Street, 27th Floor, New York, NY 10004.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit concerns alleged securities fraud committed by MoonLake Immunotherapeutics, affecting investors during a specific timeframe.
How can I participate in the lawsuit?
If you invested in MoonLake during the specified period, you can request to be appointed as lead plaintiff or simply participate in the class without additional responsibilities.
Are there any costs involved for investors?
No, if you are a class member, there is no cost incurred to participate, and you may be entitled to compensation.
Who should I contact for more information?
You can reach Joseph E. Levi at the law firm for any inquiries or additional information regarding the lawsuit.
What are the critical dates to remember?
The deadline to file for lead plaintiff status in the lawsuit is December 15, 2025.
